Joel Greenblatt Exact Sciences Corp Transaction History

Gotham Asset Management, LLC

$9.41 Billion
Q3 2024

A detailed history of Joel Greenblatt (Gotham Asset Management, LLC) transactions in Exact Sciences Corp stock. As of the latest transaction made, Gotham Asset Management, LLC holds 162,422 shares of EXAS stock, worth $8.05 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares

162,422

Previous 131,549 23.47%

Holding current value

$8.05 Million

Previous $5.56 Million 99.01%

% of portfolio

0.12%

Previous 0.07%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$42.43 - $70.83 $1.31 Million - $2.19 Million	30,873 Added 23.47%	162,422 $11.1 Million
Q2 2024 Aug 14, 2024	BUY	$41.33 - $74.26 $2.33 Million - $4.19 Million	56,440 Added 75.14%	131,549 $5.56 Million
Q1 2024 May 15, 2024	BUY	$56.27 - $73.77 $486,735 - $638,110	8,650 Added 13.02%	75,109 $5.19 Million
Q4 2023 Feb 14, 2024	SELL	$59.06 - $75.72 $1.64 Million - $2.11 Million	-27,822 Reduced 29.51%	66,459 $4.92 Million
Q3 2023 Nov 14, 2023	BUY	$65.94 - $99.04 $286,641 - $430,526	4,347 Added 4.83%	94,281 $6.43 Million
Q2 2023 Aug 14, 2023	BUY	$62.68 - $95.05 $695,748 - $1.06 Million	11,100 Added 14.08%	89,934 $8.44 Million
Q1 2023 May 15, 2023	SELL	$47.19 - $70.77 $98,438 - $147,626	-2,086 Reduced 2.58%	78,834 $5.35 Million
Q4 2022 Feb 14, 2023	BUY	$30.35 - $53.15 $1.4 Million - $2.45 Million	46,059 Added 132.12%	80,920 $4.01 Million
Q3 2022 Nov 14, 2022	BUY	$31.97 - $49.37 $1.11 Million - $1.72 Million	34,861 New	34,861 $1.13 Million
Q2 2022 Aug 15, 2022	SELL	$35.61 - $76.23 $216,936 - $464,393	-6,092 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$57.56 - $82.54 $138,028 - $197,930	-2,398 Reduced 28.24%	6,092 $426,000
Q4 2021 Feb 14, 2022	BUY	$72.5 - $100.68 $131,587 - $182,734	1,815 Added 27.19%	8,490 $661,000
Q3 2021 Nov 15, 2021	BUY	$90.24 - $124.05 $175,065 - $240,657	1,940 Added 40.97%	6,675 $637,000
Q2 2021 Aug 16, 2021	BUY	$93.66 - $139.27 $3,090 - $4,595	33 Added 0.7%	4,735 $589,000
Q1 2021 May 17, 2021	SELL	$116.57 - $155.01 $132,190 - $175,781	-1,134 Reduced 19.43%	4,702 $620,000
Q4 2020 Feb 16, 2021	SELL	$99.61 - $142.12 $102,299 - $145,957	-1,027 Reduced 14.96%	5,836 $773,000
Q3 2020 Nov 16, 2020	SELL	$72.92 - $102.01 $91,150 - $127,512	-1,250 Reduced 15.41%	6,863 $700,000
Q2 2020 Aug 13, 2020	BUY	$55.75 - $92.75 $501 - $834	9 Added 0.11%	8,113 $705,000
Q1 2020 May 15, 2020	BUY	$37.9 - $104.44 $79,552 - $219,219	2,099 Added 34.95%	8,104 $470,000
Q4 2019 Feb 14, 2020	BUY	$77.66 - $99.74 $466,348 - $598,938	6,005 New	6,005 $555,000
Q3 2019 Nov 14, 2019	SELL	$90.37 - $122.49 $324,518 - $439,861	-3,591 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$89.51 - $118.04 $3.71 Million - $4.89 Million	-41,400 Reduced 92.02%	3,591 $424,000
Q1 2019 May 15, 2019	BUY	$61.98 - $96.5 $58,509 - $91,096	944 Added 2.14%	44,991 $3.9 Million
Q4 2018 Feb 14, 2019	BUY	$56.04 - $82.66 $12,384 - $18,267	221 Added 0.5%	44,047 $2.78 Million
Q3 2018 Nov 14, 2018	SELL	$48.29 - $80.6 $2.33 Million - $3.89 Million	-48,316 Reduced 52.44%	43,826 $3.46 Million
Q2 2018 Aug 14, 2018	SELL	$37.84 - $69.96 $1.38 Million - $2.55 Million	-36,472 Reduced 28.36%	92,142 $5.51 Million
Q1 2018 May 15, 2018	SELL	$39.82 - $57.53 $3.44 Million - $4.97 Million	-86,423 Reduced 40.19%	128,614 $5.19 Million
Q4 2017 Feb 14, 2018	SELL	$46.49 - $60.51 $5.67 Million - $7.38 Million	-121,882 Reduced 36.18%	215,037 $11.3 Million
Q3 2017 Nov 14, 2017	BUY	$37.05 - $47.12 $12.5 Million - $15.9 Million	336,919	336,919 $15.9 Million

Others Institutions Holding EXAS

# of Institutions

671

Shares Held

163M

Call Options Held

2.58M

Put Options Held

2.19M

View Full List

About EXACT SCIENCES CORP

Ticker EXAS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 176,960,000
Market Cap $8.77B
Description
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...

More about EXAS

Track Joel Greenblatt's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gotham Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gotham Asset Management, LLC and Joel Greenblatt with notifications on news.

Account